Flagship Pioneering related stories
All articles and analysis
VC-backed Concert Pharmaceuticals files for IPO - FortuneFortune http://finance.fortune.cnn.com/2014/01/14/deals-of-the-day-8/ reported that Concert Pharmaceuticals has filed for a $74.75 million IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol "CNCE." UBS and Wells Fargo are the lead underwriters. Based in Lexington, Mass., Concert Pharmaceuticals produces drugs that treat spasticity and kidney disease. Its backers nclude Three Arch Partners, TVM Capital, GlaxoSmithKline, Brookside Capital, Skyline Ventures, Fidelity Investments, Greylock Partners and Flagship Ventures.
Lucky 13: Top venture capital trends in 2013IPOs and bitcoin made headlines in the year, as newsmakers Draper and Heesen stepped aside
- Visterra closes Series A
Visterra, a developer of novel therapeutics to prevent and treat major infectious diseases, has secured $8.1 million in the final closing of its Series A financing round. This financing brings the total proceeds received to date from Series A to $34.2 million. Existing investors – Polaris Venture Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation and Omega Funds – participated in the financing, as well as members of management and employees.
- Flagship Ventures launches Seres Health
Flagship VentureLabs, a unit of Flagship Ventures, has launched Seres Health after two years in stealth mode. During that period, Seres Health received $10.5 million in Series A financing from Flagship Ventures and various unnamed investors. Also, Seres Health has named Dr. Roger J. Pomerantz as chairman of its board of directors. Based in Cambridge, Mass., Seres Health is a clinical stage biotherapeutic company focused on developing drugs that target the human microbiome.
Venture firms with the most 2013 IPOsKleiner Perkins is at the top of the list followed by NEA, MPM and Meritech
- Flagship Ventures launches Seres Health
Flagship VentureLabs, a unit of Flagship Ventures, has launched Seres Health after two years in stealth mode. During that period, Seres Health received $10.5 million in Series A financing from Flagship Ventures and various unnamed investors. Also, Seres Health has named Dr. Roger J. Pomerantz as chairman of its board of directors. Based in Cambridge, Mass., Seres Health is a clinical stage biotherapeutic company focused on developing drugs that target the human microbiome.
- Biotech startup Moderna Therapeutics snags $110 mln
Moderna Therapeutics has closed $110 million in financing round. The names of the investors have not been disclosed but Flagship Ventures does have a stake in the company. Based in Cambridge, Mass., Moderna Therapeutics is a biotech startup that is developing messenger RNA drugs.
VCs embrace renewed interest in life science IPOsStrong gains by mid and large-cap biotech stocks this year have fueled a resurgence in IPOs of VC-backed life science companies
- Pronutria receives $10.8 mln in Series A funds from Flagship Ventures
Pronutria has raised $10.8 million in Series A funding from Flagship Ventures. Founded by Flagship VenturesLabs, Pronutria, which was in stealth mode for two years, identifies pharmacologically active nutrients found in the human diet.
- VC-backed BIND Therapeutics raises $70.5 mln in IPO
BIND Therapeutics, a biopharmaceutical company with venture backing, raised $70.5 million before underwriting discounts and commissions in its initial public offering of 4,700,000 shares priced at $15 per share.